Pharmaceutical News

The Cost of Attacking the Pharmaceutical Industry Trump Market Trend FDA NIH Trump's policies during his second term have rocked the U.S. scientific community, slashing NIH funding, threatening pharmaceutical innovation, and reshaping the global research landscape amid rising concerns about America's future in science.
Roche's Q1 2025 Financial report Financial statements Market Trend Roche Roche Q1 2025 financial results show 6% revenue growth, driven by strong demand for innovative drugs and diagnostics. China leads international growth, while the company makes strategic investments in the US and global R&D.
Merck's Q1 2025 Financial report Financial statements Market Trend Merck Merck's Q1 2025 earnings show a 2% decline in revenue, with strong growth in KEYTRUDA and animal health products. The company faces short-term challenges but continues to drive innovation in its R&D pipeline.
Sanofi's Q1 2025 Financial report Sanofi Financial statements Market Trend Sanofi's Q1 2025 report shows a 9.7% sales growth, driven by Dupixent and innovative drugs. The company confirms full-year guidance with strong performance in immunology, rare diseases, and vaccines.
BMS's Q1 2025 Financial report Market Trend Financial statements BMS Bristol Myers Squibb Bristol Myers Squibb Q1 2025 earnings: revenue down 6% YoY, but strong product performance drives EPS growth. Full-year guidance raised. Highlights include Opdivo, Reblozyl, and Breyanzi.
Innovative Drugs: The Changing Times FDA ADC Recent advancements in ADC therapies are reshaping cancer treatment. AstraZeneca and Gilead's breakthroughs in first-line therapies for breast and TNBC cancers mark a new era in innovative drug development.
Sanofi: Potential Super Heavy Bomb Stumbles Sanofi Sanofi's Amlitelimab, an OX40L monoclonal antibody, stumbles in asthma trials. With a strong potential in atopic dermatitis, this drug faces competition from Dupixent. OX40's future in autoimmune diseases remains promising despite challenges.
$345 Million Deal: Boehringer Ingelheim and Cue Biopharma Launch New Era in Autoimmune Disease Treatment Boehringer Ingelheim Boehringer Ingelheim partners with Cue Biopharma in a $345M deal to develop CUE-501, a next-gen bispecific antibody therapy targeting autoimmune diseases with precision and improved safety.
Johnson & Johnson's Q1 2025 Financial report Johnson & Johnson Market Trend Financial statements Johnson & Johnson's Q1 2025 report shows a 135% sales surge for CARVYKTI, a CAR-T therapy co-developed with Legend Biotech, with projected annual sales hitting $2B. Oncology drug sales also saw strong growth.
New Drug Targets Enter Clinical Trials – OMA1, CAPN2, BTM-3566 & AMX-0114 Discover groundbreaking drug targets OMA1 and CAPN2, along with promising therapies BTM-3566 and AMX-0114, entering clinical trials. Learn how they could revolutionize treatments for cancer, metabolic disorders, and neurological diseases.